Piper Sandler has reiterated its 'Overweight' rating on Boston Scientific Corp (BSX), a decision fueled by the promising outcomes of the Champion-AF study concerning the company's innovative Watchman heart implant. Analysts anticipate a significant increase in Watchman sales over the coming years, forecasting a 20% annual growth rate that is expected to bolster Boston Scientific's top-line revenue considerably. This positive outlook underscores the potential impact of the Watchman device in the medical technology sector, particularly in addressing cardiac conditions and reducing stroke risk.
Piper Sandler Reaffirms Positive Stance on Boston Scientific After Breakthrough Watchman Study
On April 6, 2026, leading financial firm Piper Sandler reaffirmed its "Overweight" rating on Boston Scientific Corp (NYSE: BSX) following the release of compelling Champion-AF study results for the company’s Watchman heart implant. The study, a pivotal evaluation of the Watchman device, focused on its efficacy and safety as a primary treatment option for stroke risk reduction. This renewal of confidence from Piper Sandler comes after a detailed discussion with a high-volume heart implant specialist, which provided valuable insights into the practical application and benefits of cardiac devices.
The Champion-AF study confirmed the Watchman heart implant met all its predefined primary and secondary endpoints for both safety and effectiveness. This outcome is particularly significant, considering that more than 59 million individuals worldwide suffer from heart rhythm disorders that could potentially be managed with such an implant. Piper Sandler projects an impressive 20% annual increase in Watchman sales for the foreseeable future, expecting this growth to contribute approximately 200 basis points to Boston Scientific’s overall revenue expansion. Boston Scientific, a global biotechnology and biomedical engineering firm established in 1979 and headquartered in Massachusetts, specializes in medical devices for cardiovascular, respiratory, and neurological conditions.
The company has demonstrated robust financial performance, with net sales in 2025 reaching $20 billion, marking a 19.9% increase. Adjusted earnings per share (EPS) also saw a healthy rise to $3.06, up from $2.51 in the previous year. Mike Mahoney, CEO of Boston Scientific, lauded 2025 as an exceptional year, highlighting the company's success in surpassing its targets. Looking ahead, Boston Scientific anticipates continued growth, forecasting a top-line growth of at least 10.5% in 2026, driven by advancements like the Watchman implant.
The successful Champion-AF study and the subsequent positive re-evaluation by Piper Sandler highlight the critical role of innovation in medical technology. The Watchman heart implant represents a significant stride in addressing stroke risk for millions globally, showcasing how targeted medical devices can profoundly impact patient care and public health. This development also underscores the importance of rigorous clinical trials in validating new treatments and the financial market's responsiveness to such breakthroughs. For investors, Boston Scientific’s sustained growth and commitment to advancing medical solutions make it a compelling subject of interest within the dynamic healthcare sector.